Press "Enter" to skip to content

Rep. Schrier Participates in Health Hearing About “Long” COVID

Advertisement

kim schrier, rep kim schrier, kim schrier 8th CD, representative kim schrier, dr. kim schrier, kim schrier 8th congressional district, rep. kim schrier M.D., Rep. Kim Schrier (D-Issaquah), 8th congressional district representative Kim Schrier, who is Kim Schrier, Kim Schrier Issaquah, Kim Schrier Immigrants, Doctor Kim Schrier, Kim Schrier Democrat, congrasswoman kim schrierCongresswoman Kim Schrier, M.D. (WA-08) participated today in an Energy and Commerce Health Subcommittee hearing on the topic of “long” COVID with officials from the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH). This term refers to a constellation of symptoms that linger for weeks to months, and perhaps even longer following COVID-19 infection. In her remarks, Rep. Schrier, a pediatrician, focused on children, and whether, as in young adults, even asymptomatic or mild COVID symptoms could lead to long-term, lingering effects related to COVID.

“We now know about long-term, devastating effects from this disease. The fact that adults with no symptoms or just mild symptoms can experience long COVID begs the question about whether children could face a similar risk despite asymptomatic or mild disease,” said Rep. Schrier. “Long COVID continues to be a medical mystery that I, like many of you, have seen in friends and constituents. I am heartened to hear that CDC and NIH are making every effort to study this mysterious COVID-19 consequence that appears to affect 10 – 30% of those who have been infected.”

Advertisement

Rep. Schrier went on to ask Dr. Brooks from the CDC about what long COVID symptoms doctors may see in children. She was told that they are noting chronic pulmonary issues, fatigue, and “brain fog.” Rep. Schrier also asked whether we have been underestimating the potential impact of this virus on children, and asked Dr. Collins from NIH about when we could expect to see the Pfizer vaccine approved for children aged 12-15, especially in light of long COVID and concerns that children could develop these long-term effects.


The above is a press release from Rep. Kim Schrier, M.D.  The Auburn Examiner has not independently verified its contents and encourages our readers to personally verify any information they find may be overly biased or questionable. The publication of this press release does not indicate an endorsement of its content. 

Advertisement
More from Health & WellnessMore posts in Health & Wellness »
More from NewsMore posts in News »
Advertisement

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

WP2Social Auto Publish Powered By : XYZScripts.com